Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

USA - NASDAQ:SRPT - US8036071004 - Common Stock

17.98 USD
-0.12 (-0.66%)
Last: 9/17/2025, 9:53:10 AM
Fundamental Rating

3

Overall SRPT gets a fundamental rating of 3 out of 10. We evaluated SRPT against 540 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SRPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRPT had negative earnings in the past year.
SRPT had a negative operating cash flow in the past year.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

With an excellent Return On Assets value of -1.57%, SRPT belongs to the best of the industry, outperforming 88.52% of the companies in the same industry.
The Return On Equity of SRPT (-4.27%) is better than 90.00% of its industry peers.
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

SRPT has a Gross Margin of 79.28%. This is amongst the best in the industry. SRPT outperforms 84.44% of its industry peers.
SRPT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SRPT has been increased compared to 1 year ago.
SRPT has more shares outstanding than it did 5 years ago.
SRPT has a better debt/assets ratio than last year.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 0.03, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
SRPT's Altman-Z score of 0.03 is fine compared to the rest of the industry. SRPT outperforms 60.19% of its industry peers.
A Debt/Equity ratio of 0.84 indicates that SRPT is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.84, SRPT is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 0.03
ROIC/WACCN/A
WACC8.27%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.89 indicates that SRPT has no problem at all paying its short term obligations.
The Current ratio of SRPT (2.89) is worse than 65.00% of its industry peers.
A Quick Ratio of 1.81 indicates that SRPT should not have too much problems paying its short term obligations.
SRPT's Quick ratio of 1.81 is on the low side compared to the rest of the industry. SRPT is outperformed by 76.48% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 1.81
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SRPT have decreased strongly by -293.33% in the last year.
The Revenue has grown by 64.89% in the past year. This is a very strong growth!
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%

3.2 Future

The Earnings Per Share is expected to grow by 6.75% on average over the next years.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.21% yearly.
EPS Next Y-309.16%
EPS Next 2Y-7.31%
EPS Next 3Y-19.39%
EPS Next 5Y6.75%
Revenue Next Year10.37%
Revenue Next 2Y-7.31%
Revenue Next 3Y-6.33%
Revenue Next 5Y-5.21%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
SRPT is valuated reasonably with a Price/Forward Earnings ratio of 9.18.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 97.22% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of SRPT to the average of the S&P500 Index (22.71), we can say SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.18
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

SRPT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SRPT is cheaper than 90.56% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 48.43
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

SRPT's earnings are expected to decrease with -19.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.31%
EPS Next 3Y-19.39%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (9/17/2025, 9:53:10 AM)

17.98

-0.12 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners96.69%
Inst Owner Change-3.06%
Ins Owners4.4%
Ins Owner Change11.51%
Market Cap1.88B
Analysts67.78
Price Target33.7 (87.43%)
Short Float %20.35%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)6.05%
PT rev (3m)-64.6%
EPS NQ rev (1m)-23.58%
EPS NQ rev (3m)-207.53%
EPS NY rev (1m)-14.36%
EPS NY rev (3m)-145.76%
Revenue NQ rev (1m)-2.51%
Revenue NQ rev (3m)-44.82%
Revenue NY rev (1m)7.01%
Revenue NY rev (3m)-19.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.18
P/S 0.76
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 1.42
EV/EBITDA 48.43
EPS(TTM)-0.87
EYN/A
EPS(NY)1.96
Fwd EY10.9%
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-2.87
OCFYN/A
SpS23.71
BVpS12.97
TBVpS12.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.28%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA 28.38
Cap/Depr 372.98%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 1.81
Altman-Z 0.03
F-Score2
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
EPS Next Y-309.16%
EPS Next 2Y-7.31%
EPS Next 3Y-19.39%
EPS Next 5Y6.75%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
Revenue Next Year10.37%
Revenue Next 2Y-7.31%
Revenue Next 3Y-6.33%
Revenue Next 5Y-5.21%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-308.31%
EBIT Next 3Y-28%
EBIT Next 5Y10.53%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A